RSS Facebook Twitter YouTube

Myeloma

FDA lifts partial clinical hold for some selinexor trials

HT Staff Read Article
Published: 03/30/17

preparing_capsules_for_a_clinical_trial_credit_Esther_Dyson_230.jpg
Preparing treatment for a trial
Photo by Esther Dyson

The US Food and Drug Administration (FDA) has lifted the partial clinical hold on trials of selinexor (KPT-330) in patients with hematologic malignancies. The partial clinical hold, which was announced on March 10, was placed on all trials of the drug, including studies of patients with solid tumor malignancies. The hold meant that no new patients could be enrolled in selinexor trials. Patients who were already enrolled and had stable disease or better could remain on selinexor therapy.  [Read Article]

Inpatient palliative care improves QOL for HSCT patients

Erilyn Riley Read Article
Published: 02/27/17

doctor_and_hospitalized_patient_smiling_Credit_CDC_230.jpg
Doctor and hospitalized patient
Photo courtesy of CDC

New research shows that patients who received inpatient palliative care while undergoing hematopoietic stem cell transplant (HSCT) experienced significant improvements in quality of life (QOL), decreases in depression, and reductions in symptom burden compared to patients who received transplant care alone. Areej R. El-Jawahri, MD, of Harvard Medical School in Boston, Massachusetts, presented these results at the 2017 BMT Tandem Meetings. [Read Article]

CHMP recommends authorization of antiemetic agent

HT Staff Read Article
Published: 02/27/17

patient_receives_chemo_older_woman_Credit_Rhoda_Baer_220.jpg
Cancer patient
receiving chemotherapy
Photo by Rhoda Baer

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for the antiemetic agent rolapitant (Varuby) as a treatment for adults with cancer. The drug is intended to be used in combination with other antiemetic agents to prevent delayed nausea and vomiting associated with highly and moderately emetogenic chemotherapy. [Read Article]

CHMP recommends new indication for daratumumab

HT Staff Read Article
Published: 02/25/17

daratumumab-230.jpg
Daratumumab (Darzalex)
Photo courtesy of Janssen

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended broadening the existing marketing authorization for daratumumab (Darzalex®) in the European Union. The CHMP recommended approving daratumumab in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone as treatment for adults with multiple myeloma (MM) who have received at least 1 prior therapy.  [Read Article]

Oncolytic virus can eradicate MM in mice

HT Staff Read Article
Published: 02/24/17

bartee-eric-phd-musc-220.jpg
Eric Bartee, PhD
Photo from the Medical
University of South Carolina

Myxoma virus (MYXV), a nonhuman oncolytic agent, has demonstrated efficacy in mouse models of multiple myeloma (MM), according to research published in Molecular Therapy—Oncolytics. MYXV significantly improved overall survival in mice with MM, providing a modest delay in disease progression for about two-thirds of the mice and completely eradicating the disease in a quarter of them. “[W]e could actually get rid of disease, and it didn’t appear to ever come back . . . [Read Article]

 

{title}

{icon} {author} Read Article
Published: {pubDate}

{summary}